These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 33508124)

  • 1. Long-term mortality and trajectory of potassium measurements following an episode of acute severe hyperkalaemia.
    Gorriz JL; D'Marco L; Pastor-González A; Molina P; Gonzalez-Rico M; Puchades MJ; Sanchis I; Escudero V; Estañ N; de la Espriella R; Nuñez E; Pallardó L; Núñez J
    Nephrol Dial Transplant; 2022 Feb; 37(3):522-530. PubMed ID: 33508124
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term safety and efficacy of sodium zirconium cyclosilicate for hyperkalaemia in patients with mild/moderate versus severe/end-stage chronic kidney disease: comparative results from an open-label, Phase 3 study.
    Roger SD; Lavin PT; Lerma EV; McCullough PA; Butler J; Spinowitz BS; von Haehling S; Kosiborod M; Zhao J; Fishbane S; Packham DK
    Nephrol Dial Transplant; 2021 Jan; 36(1):137-150. PubMed ID: 32030422
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Plasma potassium ranges associated with mortality across stages of chronic kidney disease: the Stockholm CREAtinine Measurements (SCREAM) project.
    Gasparini A; Evans M; Barany P; Xu H; Jernberg T; Ärnlöv J; Lund LH; Carrero JJ
    Nephrol Dial Transplant; 2019 Sep; 34(9):1534-1541. PubMed ID: 30085251
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prevalence and factors associated with hyperkalaemia in stable kidney transplant recipients.
    Smyrli M; Sarafidis PA; Loutradis C; Korogiannou M; Boletis IN; Marinaki S
    Clin Kidney J; 2022 Jan; 15(1):43-50. PubMed ID: 35035935
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serum potassium as a predictor of adverse clinical outcomes in patients with chronic kidney disease: new risk equations using the UK clinical practice research datalink.
    Furuland H; McEwan P; Evans M; Linde C; Ayoubkhani D; Bakhai A; Palaka E; Bennett H; Qin L
    BMC Nephrol; 2018 Aug; 19(1):211. PubMed ID: 30134846
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A determination of the current causes of hyperkalaemia and whether they have changed over the past 25 years.
    Muschart X; Boulouffe C; Jamart J; Nougon G; Gérard V; de Cannière L; Vanpee D
    Acta Clin Belg; 2014 Aug; 69(4):280-4. PubMed ID: 24942977
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hyperkalemia Recurrence Following Medical Nutrition Therapy in Patients with Stage 3-4 Chronic Kidney Disease: The REVOLUTIONIZE I Real-World Study.
    Rowan CG; Agiro A; Chan KA; Colman E; White K; Desai P; Dwyer JP
    Adv Ther; 2024 Jun; 41(6):2381-2398. PubMed ID: 38687454
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association of hyperkalemia with clinical outcomes in advanced chronic kidney disease.
    Caravaca-Fontán F; Valladares J; Díaz-Campillejo R; Barroso S; Luna E; Caravaca F
    Nefrologia (Engl Ed); 2019; 39(5):513-522. PubMed ID: 31027897
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Management of hyperkalaemia in chronic kidney disease.
    Kovesdy CP
    Nat Rev Nephrol; 2014 Nov; 10(11):653-62. PubMed ID: 25223988
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prevalence, clinical impact and costs of hyperkalaemia: Special focus on heart failure.
    Maggioni AP; Dondi L; Andreotti F; Calabria S; Iacoviello M; Gorini M; Gonzini L; Piccinni C; Ronconi G; Martini N
    Eur J Clin Invest; 2021 Aug; 51(8):e13551. PubMed ID: 33786826
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-Term Potassium Monitoring and Dynamics in Heart Failure and Risk of Mortality.
    Núñez J; Bayés-Genís A; Zannad F; Rossignol P; Núñez E; Bodí V; Miñana G; Santas E; Chorro FJ; Mollar A; Carratalá A; Navarro J; Górriz JL; Lupón J; Husser O; Metra M; Sanchis J
    Circulation; 2018 Mar; 137(13):1320-1330. PubMed ID: 29025765
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Experience with the potassium binder patiromer in hyperkalaemia management in heart failure patients in real life.
    Esteban-Fernández A; Ortiz Cortés C; López-Fernández S; Recio Mayoral A; Camacho Jurado FJ; Gómez Otero I; Molina M; Almenar Bonet L; López-Vilella R
    ESC Heart Fail; 2022 Oct; 9(5):3071-3078. PubMed ID: 35748119
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of the efficacy and safety of RLY5016, a polymeric potassium binder, in a double-blind, placebo-controlled study in patients with chronic heart failure (the PEARL-HF) trial.
    Pitt B; Anker SD; Bushinsky DA; Kitzman DW; Zannad F; Huang IZ;
    Eur Heart J; 2011 Apr; 32(7):820-8. PubMed ID: 21208974
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic significance of serum potassium in patients hospitalized for acute heart failure.
    Lombardi CM; Carubelli V; Peveri G; Inciardi RM; Pagnesi M; Ravera A; Tomasoni D; Garafa E; Oriecuia C; Specchia C; Metra M
    ESC Heart Fail; 2022 Aug; 9(4):2357-2366. PubMed ID: 35543336
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serum potassium abnormalities in chronic kidney disease: prevalence, patient characteristics and clinical outcomes.
    Brookes EM; Snider J; Hart GK; Robbins R; Power DA
    Intern Med J; 2021 Nov; 51(11):1906-1918. PubMed ID: 33314585
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The burden of hyperkalaemia on hospital healthcare resources.
    Logan Ellis H; Al-Agil M; Kelly PA; Teo J; Sharpe C; Whyte MB
    Clin Exp Med; 2024 Aug; 24(1):190. PubMed ID: 39136879
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Epidemiology of hyperkalemia in chronic kidney disease.
    Belmar Vega L; Galabia ER; Bada da Silva J; Bentanachs González M; Fernández Fresnedo G; Piñera Haces C; Palomar Fontanet R; Ruiz San Millán JC; de Francisco ÁLM
    Nefrologia (Engl Ed); 2019; 39(3):277-286. PubMed ID: 30898450
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hyperkalemia in chronic heart failure with renal dysfunction or diabetes mellitus: Results from the TREAT HF study.
    Murat S; Kaya H; Çavuşoğlu Y; Yılmaz MB
    Turk Kardiyol Dern Ars; 2021 Apr; 49(3):198-205. PubMed ID: 33847269
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serum potassium variability as a predictor of clinical outcomes in patients with cardiorenal disease or diabetes: a retrospective UK database study.
    James G; Kim J; Mellström C; Ford KL; Jenkins NC; Tsang C; Evans M; McEwan P
    Clin Kidney J; 2022 Apr; 15(4):758-770. PubMed ID: 35371436
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Recurrent hyperkalaemia management and use of renin-angiotensin-aldosterone system inhibitors: Analysis of French data from the PROKALE multinational European study].
    Rossignol P;
    Nephrol Ther; 2021 Oct; 17(6):422-427. PubMed ID: 33994135
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.